KRAS and non-small cell lung carcinoma: Mutations in EGFR are common oncogenes in LC, such as the T190 M mutation in EGFR, which was found to be the most prevalent in NSCLC patients with drug resistance to tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib.[27] KRAS, the most common driver mutation in patients with NSCLC, was the second most frequently mutated gene.